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The Role of Neuronal Complexes in Human X-Linked Brain
Diseases
Fre´de´ric Laumonnier, Peter C. Cuthbert, and Seth G. N. Grant
Beyond finding individual genes that are involved in medical disorders, an important challenge is the integration of sets
of disease genes with the complexities of basic biological processes. We examine this issue by focusing on neuronal
multiprotein complexes and their components encoded on the human X chromosome. Multiprotein signaling complexes
in the postsynaptic terminal of central nervous system synapses are essential for the induction of neuronal plasticity
and cognitive processes in animals. The prototype complex is the N-methyl-D-aspartate receptor complex/membrane-
associated guanylate kinase–associated signaling complex (NRC/MASC) comprising 185 proteins and embedded within
the postsynaptic density (PSD), which is a set of complexes totaling ∼1,100 proteins. It is striking that 86% (6 of 7) of
X-linked NRC/MASC genes and 49% (19 of 39) of X-chromosomal PSD genes are already known to be involved in human
psychiatric disorders. Moreover, of the 69 known proteins mutated in X-linked mental retardation, 19 (28%) encode
postsynaptic proteins. The high incidence of involvement in cognitive disorders is also found in mouse mutants and
indicates that the complexes are functioning as integrated entities or molecular machines and that disruption of different
components impairs their overall role in cognitive processes. We also noticed that NRC/MASC genes appear to be more
strongly associated with mental retardation and autism spectrum disorders. We propose that systematic studies of PSD
and NRC/MASC genes in mice and humans will give a high yield of novel genes important for human disease and new
mechanistic insights into higher cognitive functions.
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The synapse is fundamentally important for neural func-
tion because it mediates the interneuron communication
that forms the basis of all cognitive activity.1–4 The ma-
jority of synapses in the CNS use glutamate as a neu-
rotransmitter.5,6 Glutamate is released from presynaptic
terminals in response to incoming action potentials, dif-
fuses across the synaptic cleft, and activates receptors
embedded in the postsynaptic membrane.7,8 The main
types of glutamate receptors are ion-channel–forming N-
methyl-D-aspartic acid (NMDA), a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA), and G protein–
coupled metabotropic (mGluR) receptors (fig. 1A). The
primary role of AMPA receptors is to mediate the mem-
brane depolarization that is necessary to initiate action
potentials in the postsynaptic neuron. By contrast, the
NMDA and mGluR receptors do not significantly contrib-
ute to the depolarization but do initiate signal transduc-
tion–pathway signaling. Moreover, NMDA and mGluR re-
ceptors are physically linked by scaffolding proteins and
are found within multiprotein complexes, along with sig-
naling enzymes and other proteins.10–13
Pharmacological antagonists for the glutamate receptors
have been available for 120 years and have been used
extensively in animal and human studies, and it is clear
that these receptors play a role in a diverse set of be-
haviors.14,15 These findings have led to the “glutamate hy-
pothesis” of mental illnesses.16,17 Although there is no
doubt that glutamate receptors are physiologically im-
portant, progress in several areas has dramatically ex-
panded our understanding of their role in synapse biology.
First, it is known that the receptors physically link to a
plethora of proteins and form signaling and trafficking
complexes (discussed in detail below); second, synapse
proteomics has characterized multiprotein complexes and
has discovered hundreds of postsynaptic proteins, many
of which are involved with human disease; and, third,
genetic manipulation of synapse proteins in mouse has
overcome the limited availability of pharmacological an-
tagonists and, hence, has allowed the functional testing
of specific genes in behaviors. Given the large amount of
available data within these different areas of investigation,
it is timely to integrate these data sets and to ask how they
might be useful in future human genetic studies of brain
diseases.
We will address a number of general issues relevant to
any tissue or disease, using the extensive information on
synapse proteins and specific multiprotein complexes. In-
terrogating these lists and models with human genetic
data allows several questions to be addressed. First, how
many of the genes encoding the components of a complex
are involved with human disease? Second, are there sim-
ilarities in the phenotypes that might indicate that the
mutations have interfered with the overall function of the
complex? Third, what do the human phenotypes reveal
about the physiological or cellular functions of the com-
plex? Fourth, can we confidently use the gene lists to hunt
for further disease-causing mutations? Fifth, can under-
standing the interaction of proteins in the complexes pro-
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Figure 1. The PSP of a glutamatergic excitatory synapse. A, The
PSP, the complement of postsynaptic proteins that contains
∼1,180 proteins. This set of proteins is organized into complexes
of varying sizes (B). The function of postsynaptic complexes is to
receive and process signals that mediate neuronal communication
and synaptic and behavioral plasticity. NMDA, AMPA, and mGLuR
subtypes of glutamate receptors are indicated. B, Venn diagram
of constituent protein complexes of the PSP (adapted from Grant9).
The total set of PSP (1,180 proteins) is represented as sets of
complexes (NRC/MASC, mGLuR5, AMPA, and PSD), and the number
of proteins in these sets and overlaps are indicated. Details of the
specific proteins are found in table A1 (online only).
vide useful models for understanding genetic interactions,
such as epistasis, or polygenic disorders? We will address
these issues, using data on neurological phenotypes in
humans with X-linked disorders and data from studies of
proteins found on the postsynaptic side of mammalian
brain synapses. This focus provides a more in-depth view
from which we can learn lessons used to guide studies on
all autosomes as well as larger sets of brain genes.
The Synapse and the Postsynaptic Proteome
By analogy with genome projects that aim to provide com-
prehensive lists of genes, synapse proteomics aims to pro-
duce comprehensive lists of proteins that are found in
synapses. The postsynaptic proteome (PSP) is the com-
plement of proteins localized within the postsynaptic ter-
minal, and recent large-scale efforts to characterize the PSP
have produced a comprehensive description of its con-
stituents.18–23 These studies were performed by the bio-
chemical fractionation of the synapse and by subsequent
protein identification with the use of mass spectrometry
and antibody-based methods. Meta-analysis of these data
sets indicates that the PSP contains ∼1,180 proteins in a
number of distinct structural and functional complexes
(fig. 1B and table A1 [online only]). The largest of these
complexes is the postsynaptic density (PSD), a dense struc-
ture directly below the postsynaptic membrane that is vis-
ible by electron microscopy24,25 and that comprises ∼1,124
proteins (table A1 [online only] and the Genes to Cog-
nition [G2C] Web site). It is worth noting that these lists
are not definitive, since some proteins escape detection
and some proteins will be contaminants from the frac-
tionation procedure.
The PSD contains many different classes of proteins rep-
resenting a broad range of cell biological functions, in-
cluding membrane-bound receptors (including the glu-
tamate receptors), adhesion proteins and channels, sig-
naling proteins and adaptors, and proteins involved in
transport, RNA metabolism, and transcription and trans-
lation (table A1 [online only]).18–23 Compared with the en-
tire mouse proteome, PSD proteins are enriched in protein
interaction domains and, in particular, in PDZ (PSD-95,
Discs-large, ZO-1) and SH3 (Src homology 3) domains,
consistent with the abundance of adaptor and scaffolding
proteins. There is also enrichment of kinase, calcium-de-
pendent signaling, and Ras guanosine triphosphatase
(GTPase) domains.20
The glutamate receptor complexes are subsets of the PSP,
and there is considerable overlap between the various
complexes (fig. 1B). Affinity purification of NMDA recep-
tor complexes (NRC) or affinity isolation of membrane-
associated guanylate kinase (MAGUK) proteins, which di-
rectly bind NMDA receptors, resulted in 185 proteins.10,20
These complexes are alternatively known as the “NRC” or
the “MASC” (MAGUK-associated signaling complexes),
since both isolation procedures result in a similar set of
proteins. Within the NRC/MASC can be found the NMDA
and mGluR subunits, whereas AMPA-receptor subunits are
in separate and smaller complexes (nine proteins).20
Through affinity isolation, mGluR5 receptor complexes
were found to contain 76 proteins.26 The initial observa-
tions that NMDA and mGluR receptors were associated
with dozens of proteins were surprising; however, since
then, a substantial number of binary protein-interaction
studies have mapped the interactions in detail. Moreover,
many of the proteins in the NRC/MASC are known to
mediate the signaling functions of the receptors.27,28 As
suggested by the Venn diagram in figure 1B, the PSP is a
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set of complexes embedded within the PSD and has often
been referred to as a “supramolecular” complex.29
The NRC/MASC is the most well studied of these large
postsynaptic complexes and can be considered a proto-
type for the overall PSP. The physiological role of NRC/
MASC proteins has been investigated using knockout mice
and pharmacological intervention, most typically with
the use of brain slices in which synaptic plasticity has been
induced. More than 40 NRC proteins are necessary for the
process of converting patterns of neuronal activity into
long-lasting changes in neuronal function, and a similar
number are required for behavioral forms of plasticity in
rodents, such as learning or fear conditioning.27,28,30 These
numbers continue to increase as further genes are tested,
which reinforces the model that the NRC/MASC is a sig-
naling complex involved with the basic process of neural
plasticity.
In addition to the accumulation of mouse genetic and
phenotypic data on NRC/MASC proteins, the binary in-
teractions of proteins within the complexes have been
mapped and used to generate protein-interaction net-
works.27,28 The average number of protein interactions sep-
arating any pair of NRC/MASC proteins is very low (av-
erage shortest path length 3.3), suggesting that the
complex consists of a large network containing multiple
clusters of well-connected proteins rather than a system
of linear pathways with occasional interconnections. Al-
gorithm-based network cluster analysis indicates that the
complex contains 13 clusters, each with distinct func-
tional characteristics and phenotypic associations (fig. 2).
The flow of information through the complex is modeled
in figure 3. In essence, the glutamate receptors and their
proximal associated proteins form “input” modules,
which then connect to a large set of general signaling
proteins referred to as “processing” modules, which then
signal to “output” modules comprising some well-known
effector-pathway components, such as the extracellular
signal-regulated kinase (ERK)/mitogen-activated protein
kinase (MAPK) pathway (see the work of Pocklington et
al.27 and Pocklington et al.28 for details of the networks).
The mouse and human mutations that result in plasticity
or behavioral deficits were mapped onto this network, and
some interesting distributions of phenotypes were seen in
particular modules. Although it is clear that this type of
systems-biology approach will benefit from systematic
mutational studies like those done in yeast,31,32 it dem-
onstrates that molecular network maps of synaptic protein
complexes can be used to help understand the functional
relationships between proteins. At the very least, it pro-
vides a logic for assembling a disparate set of genetic stud-
ies into a unified model.
These proteomic and mouse genetic studies serve as a
driver for human genetic studies, since it would seem
likely that many of the proteins would be involved in
human disease. Indeed, when the NRC was first charac-
terized, it was recognized that three proteins were well
known to be mutated in neurological diseases.10 A recent
data-mining and literature-curation study revealed that 54
NRC/MASC proteins are involved with both psychiatric
and neurological conditions.27,30 A considerable number
of these disorders have cognitive components (e.g., au-
tism, schizophrenia, and mental retardation [MR]) con-
sistent with mouse genetic studies showing specific im-
pairments in cognitive function.27,30
The X Chromosome as a Model for the Genetics
of Cognition
In recent decades, the role of the X chromosome in cog-
nition has been extensively studied. Although it is known
that genes influencing cognitive function are distributed
throughout the human genome, many more “cognition
genes” have been found on the X chromosome than on
comparable segments of the autosomes.33 In parallel with
these observations, numerous epidemiological studies per-
formed to evaluate the sex ratio in autism and MR have
indicated an excess of males, suggesting a preferential as-
sociation between genetic defects and cognitive disorders
in males.34–38 Males outnumber females in nearly all sur-
veys of MR, with an excess of ∼20%, and numerous fam-
ilies have been reported in which MR segregated in an X-
linked inheritance pattern. X-linked MR (XLMR) is a
common cause of moderate to severe intellectual disability
in males, with a prevalence of 2.6 cases per 1,000 in the
general population, accounting for 110% of all cases of
MR.39,40 Although highly heterogeneous, XLMR is usually
divided into syndromic forms (MRXS), which have asso-
ciated musculoskeletal or metabolic symptoms, and non-
syndromic (or nonspecific) forms (MRX) in which MR is
the sole feature, although accumulating evidence suggests
that this boundary is less evident than was previously
expected.35,41 So far, 1140 MRXS conditions have been re-
ported; in almost half of these, causative mutations in
genes have been described.40–42
The publication of the genomic sequence of the human
X chromosome provided a comprehensive data set of the
genes and their organization.43,44 Approximately 1,100
genes have been annotated on the X chromosome, of
which at least 800 are protein coding.43,45,46 The features
of the gene organization on the X chromosome are low
gene number and density and enrichment for genes ex-
pressed in testis, brain, skeletal muscle, ovary, and pla-
centa.43,47 Although it accounts for only 4% of all identi-
fied human genes, this chromosome includes genes re-
sponsible for almost 10% of diseases with known Men-
delian inheritance.43 The mammalian X chromosome is
very different from the autosomes because of its unequal
representation in males (1 copy) and females (2 copies).
To compensate for this unequal dose, females inactivate
one copy of the X chromosome in every cell. Thus, this
chromosome is of particular interest for medical genetics,
since numerous disease conditions have been associated
with the X chromosome because the phenotypic conse-
Fi
gu
re
2.
Pr
ot
ei
n-
in
te
ra
ct
io
n
ne
tw
or
k
of
th
e
NR
C/
M
AS
C
co
m
pl
ex
.
A
ne
tw
or
k
of
bi
na
ry
in
te
ra
ct
io
ns
be
tw
ee
n
NR
C/
M
AS
C
pr
ot
ei
ns
w
as
cl
us
te
re
d
in
to
“m
od
ul
es
”
w
it
h
th
e
us
e
of
al
go
ri
th
m
s.
28
Th
es
e
13
nu
m
be
re
d
cl
us
te
rs
ar
e
gr
ou
pe
d
in
to
th
re
e
la
ye
rs
:“
in
pu
t,
”
re
pr
es
en
ti
ng
th
e
ne
ur
ot
ra
ns
m
it
te
rr
ec
ep
to
rs
an
d
pr
ox
im
al
in
te
ra
ct
in
g
pr
ot
ei
ns
;“
pr
oc
es
si
ng
,”
ge
ne
ra
l
si
gn
al
in
g
pr
ot
ei
ns
;
an
d
“o
ut
pu
t,
”
do
w
ns
tr
ea
m
se
ts
of
si
gn
al
in
g
pr
ot
ei
ns
su
ch
as
ER
K/
M
AP
K
pa
th
w
ay
s.
Re
pr
in
te
d
w
it
h
pe
rm
is
si
on
fr
om
M
ol
ec
ul
ar
Sy
st
em
s
Bi
ol
og
y.
www.ajhg.org The American Journal of Human Genetics Volume 80 February 2007 209
Figure 3. Modular signaling mechanisms of postsynaptic complexes. The modules of clustered proteins are organized into layers of
signaling, with synaptic cleft at the top. Presynaptic information, in the form of a neurotransmitter, enters the postsynaptic signaling
machinery via activation of ionotropic and metabotropic transmembrane receptors that are in modules of proximal signaling proteins
(blue). From there, signals are passed to a large information-processing module (red) and then are distributed to effector mechanism
networks (green), which mediate a functional outcome (dark blue arrow).28 This signaling machinery provides a high degree of signal
integration by protein interaction and orchestration of output responses.
quences of a recessive mutation are revealed directly in
males.41,44,48
In the last Ensembl data release (National Center for
Biotechnology Information database release 39) and with
the use of the large-scale data-mining tool BioMart
(MartView software), we found that 1500 genes located
on the X chromosome are expressed in the human brain,
thus representing numerous potential candidates for X-
linked brain diseases. Many classes of proteins are repre-
sented, ranging from transcription factors, channels and
receptors, and DNA/RNA–binding proteins to scaffolders,
enzymes, and signal-transduction proteins. These large
data sets, rich in human genetic data, as well as repre-
senting many brain genes of different functions, provide
an ideal tool for systematically analyzing the postsynaptic
proteins and their signaling complexes.
X-Linked Diseases and Postsynaptic Complexes
To address the role of the NRC/MASC and the PSD in X-
linked brain diseases, we annotated the X-chromosome
genes encoding components of these complexes. Table 1
summarizes the total numbers and functional classifica-
tion of PSD and NRC/MASC genes, those on the X chro-
mosome, and those that are mutated in XLMR. The X
chromosome was not enriched for NRC/MASC or PSD
genes, since 3.7% (39 of 1,124) of NRC/MASC and 3.2%
(6 of 186) of PSD genes were encoded on X, which is
similar to the 4% of all coding genes found on this chro-
mosome. A high proportion of the X-linked genes coding
PSD and NRC/MASC proteins were found to be mutated
in psychiatric disorders: 19 (49%) of 39 PSD genes and 6
(85%) of 7 NRC/MASC genes. These proportions are likely
to increase, since some of these genes that have no as-
sociated human disorder are known to result in abnormal
phenotypes in knockout mice (table 2). A specific list of
these genes is provided in table 3, since they are suitable
targets for future resequencing efforts.
Multiple functional groups of proteins were represented,
with the most abundant being signaling molecules and
enzymes representing 10 proteins, which were 125% of
the total X-linked PSD proteins. Of the 10 specific func-
tional categories of PSD proteins, 8 were encoded on the
X chromosome, and there are human mutations in all 8
categories (table 1). We noted that all (6 of 6) cytoskeletal
and adhesion proteins (PLP1 [MIM 300401], DMD [MIM
300377], FLNA [MIM 300017], L1CAM [MIM 308840],
NLGN3 [MIM 300336], and NLGN4 [MIM 300427]) and
all (2 of 2) serine/threonine kinases (CDKL5 [MIM 300203]
and RPS6KA3 [MIM 300075]) were mutated in brain dis-
eases (tables 1 and 2).
The multiple classes of proteins involved in XLMR and
the heterogeneity of proteins in the PSP allow a unification
of the two data sets. In other words, if one were to consider
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Table 1. Functional Classification of Synapse Proteome Proteins and Their
Representation on the X Chromosome
Functional Classificationa
No. of Proteins inb
PSD NRC/MASC
Total X-Linked Mutated Total X-Linked Mutated
Channels and receptors 80 4 2 12 0 0
MAGUKs/adaptors/scaffolders 54 4 1 20 1 1
Ser/thr kinases 46 2 2 21 1 1
Tyr kinases 3 0 0 2 0 0
Protein phosphatases 18 0 0 7 0 0
G proteins and modulators 77 3 2 19 0 0
Signaling molecules and enzymes 278 10 3 40 0 0
Transcription and translation 119 5 2 5 0 0
Cytoskeletal and cell-adhesion molecules 153 6 6 35 4 4
Synaptic vesicles and protein transport 159 3 1 22 1 0
Novel 107 2 0 3 0 0
Other 30 0 0 0 0 0
Summary 1,124 39 19 186 7 6
a Proteins found in PSD and NRC/MASC profiling experiments were classified into functional groups (see
the work of Collins et al.11).
b The total number of proteins in the complex (Total), the number on the X chromosome (X-linked), and
the number known to be mutated in XLMR (Mutated) are indicated for each protein class. Note that almost
50% (19 of 39) of the X-linked genes coding for PSD proteins and 85% (6 of 7) of MASC genes are mutated
in nervous-system diseases.
the genetic data alone, then the heterogeneity would be
accounted for in terms of a diverse range of mechanisms
contributing to XLMR. However, the fact that many com-
ponents from this heterogeneous list are found within the
NRC/MASC or the PSD indicates that the mutations may
have a single general mechanism at the level of their func-
tion in the multiprotein complex. In other words, the
overall function of the complex can be impaired by mu-
tation in different proteins in the complex. This does not
mean that the mutations should have identical functions,
since the specific role of the proteins in the complexes
will differ, although they have a common overall function.
This model is strongly supported by mouse genetic data
and synaptic physiology for core components of NRC/
MASC, where mutations in different classes of proteins
result in changes in synaptic plasticity.49–51
Functions of Specific X-Linked NRC/MASC
and PSD Genes
We will now address the details of specific genes and their
phenotypes in humans and mice. Table 2 provides further
details of the 39 PSD X-linked genes, including their func-
tions, human disorders, and mouse models. With a focus
on the seven X-linked NRC/MASC genes (DLG3, RPS6KA3,
PLP1 [MIM 300401], L1CAM, SLC25A5 [MIM 300150],
NLGN3, and NLGN4), six are associated with brain dis-
eases. Only the SLC25A5 gene, which encodes a mito-
chondrial adenosine diphosphate or triphosphate (ADP/
ATP) translocase, has not been involved in XLMR, and it
is possible that this translocase is a contaminant of the
proteomic experiment. These proteins and other NRC/
MASC proteins are schematically represented in figure 4,
which also illustrates the genes implicated in human and
mouse diseases.
The DLG3 (discs large, Drosophila, homolog of, 3) gene
encodes the synapse-associated protein 102 (SAP102), a
member of the MAGUK protein family.53,54 SAP102 and
other MAGUK proteins (e.g., PSD-95 and PSD-93/chapsyn-
110) are multidomain scaffold proteins that bind the
NMDA receptor and other signaling and cytoskeletal
proteins.1,7 Human mutations in DLG3 are associated with
MR,55 and mouse knockouts result in learning deficits and
alterations in the MAPK signaling pathway.56
Mutations in NLGN3 and NLGN4 (neuroligin 3 and 4)
were found in XLMR and/or autism.57,58 A wide spectrum
of phenotypes, ranging from mild MR without commu-
nication deficits to Asperger syndrome with normal or
supranormal intelligence, were reported.58 Functional
analyses performed in hippocampal neuronal cultures
where Nlgn 1, 2, and 3 were knocked down showed altered
dendritic spines and a reduction in dendritic branching
and arborization.59 Others studies suggest that neuroligins
affect, in combination with PSD-95, the direction of de-
velopment into an inhibitory or excitatory synapse in vi-
tro.60–62 Interestingly, the recent publication63 of the triple-
knockout mouse for Nlgn 1–3 showed that the animals die
shortly after birth because of respiratory failure. However,
Varoqueaux et al. noticed that the density of synaptic con-
tacts is not altered in neuroligin-deficient brains, indicat-
ing that neuroligins are required for proper synapse mat-
uration and brain function but not for the initial
formation of synaptic contacts.63
The L1CAM gene encodes the L1 protein, which is a
highly conserved member of the immunoglobulin-like
family of cell-adhesion glycoprotein molecules. During
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development, L1 is expressed in neurons throughout the
brain and is involved in neurite outgrowth, axonal guid-
ance, synaptogenesis, myelination, and fasciculation.64–66
Mutations in L1 affect development of the nervous system
in human and mouse: they are responsible for a form of
MRXS described as “X-linked hydrocephalus,” “MASA
syndrome” (MR, aphasia, shuffling gait, and adductus
thumbs), or “spastic paraplegia type I” (SPG1).64 L1 dis-
ruption in mice also produces a cognitive defect, and ab-
normalities of the hippocampus and the morphology of
individual neurons were reported.67 A recent study showed
that the MAPK pathway (involving mitogen-activatedpro-
tein kinase kinase [MEK] and ERK) regulates L1CAM-me-
diated nerve growth by phosphorylating L1CAM and then
modulating its interaction with ankyrin B (see fig. 4).68
The RPS6KA3 gene encoding the 90-kDa ribosomal S6
serine-threonine kinase-2 (RSK2) is mutated in both MRXS
(e.g., Coffin-Lowry syndrome)69 and MRX.70 In the CNS,
the ERK signaling pathway activates RSK2 and leads to
protein kinase A (PKA)–dependent activation of cyclic
adenosine monophosphate response element–binding
(CREB) protein in the hippocampus and to the regulation
of neuronal synaptic plasticity (fig. 4).71 Interestingly, a
study performed by Naisbitt et al. suggested that RSK2
directly binds by a C-terminal motif and/or phosphoryl-
ates Shank1 (SH3 and multiple ankyrin-repeat domains 1
[MIM 604999]), Shank3 (MIM 606230), Magi-1 (MAGUK,
WW and PDZ domain–containing 1 [MIM 602625]) and
Grip1 (glutamate receptor–interacting protein 1 [MIM
604597]), which are then tethered to the NRC/MASC by
Shank interactors, such as guanylate kinase–associated
proteins (GKAP) or Homer, which belong to the PSP.72
They also demonstrated that signaling via RSK2 seems to
regulate AMPA-receptor transmission (such as the X-
linked GRIA3 protein).73
The proteolipid protein 1 (PLP1) is the major integral
membrane protein of adult CNS myelin.74 PLP1 is syn-
thesized at the endoplasmic reticulum (ER) and then is
transported to the cell surface, where it is incorporated
into the myelin membrane. The primary role of PLP1 in
myelin formation is currently thought to be the adhesion
and stabilization of the extracellular surfaces of the myelin
membrane, although some evidence suggests that PLP1
may function as a channel-forming protein.75 Mutations
in the PLP1 gene are associated with forms of MRXS, in-
cluding Pelizaeus-Merzbacher disease and X-linked SPG1.
Mutant forms of PLP1 are retained in the ER, and the
resulting accumulation of mutant protein is thought to
be a direct cause of oligodendrocyte cell death.76 The PLP1
protein has been found in different PSD purification stud-
ies, thus suggesting a postsynaptic subcellular localization
in the neuronal cell.19–21,23 Recently, Gudz et al. found that,
after agonist activation of the AMPA receptor, the PLP1,
avb3 integrin, and the AMPA receptor proteins form a com-
plex.77 These data are particularly interesting, since this
protein is not typically considered to be postsynaptic. An-
other link between PLP1 and NRC/MASC may be provided
by the recent observation that oligodendrocytes express
NMDA receptors, which are important for aspects of
ischemia.78,79
Turning our attention from the NRC/MASC, which can
be considered a signaling complex embedded within a
much larger set of proteins forming the PSD, we address
the functions of specific PSD genes involved in human X-
linked disorders. The channel and receptors group in-
cludes the GRIA3 (glutamate receptor, ionotropic, AMPA
3 [MIM 305915]) and IL1RAPL1 (interleukin 1 receptor
accessory protein-like 1 [MIM 300206]) genes. The GRIA3
gene encodes the AMPA receptor GLUR3, which mediates
fast synaptic transmission in the CNS.80 This gene has been
previously described in a female with MR and bipolar af-
fective disorder and a balanced X-autosome translocation
truncating the GRIA3 gene.81 Very recently, three missense
mutations at evolutionarily conserved positions of the
GRIA3 gene have been characterized in three unrelated
males with MR.82 Analyses of knockout mice for Gria3
revealed an enhanced long-term potentiation of synaptic
transmission, which indicates a role of GRIA3 in the reg-
ulation of synaptic plasticity.80
The IL1RAPL1 gene, mutated in several families with
MRX,83 codes for a receptor protein that interacts with the
neuronal calcium sensor-1 protein (a member of a large
Ca2-binding protein family) through its cytoplasmic C-
terminal domain.84 IL1RAPL may be involved in the reg-
ulation of calcium-dependent exocytosis and, therefore,
in synaptic activity.84
The HADH2 (hydroxyacyl-CoA dehydrogenase, type II
[MIM 300256]), MAOA (monoamine oxidase A [MIM
309850]), and PRPS1 (phosphoribosylpyrophosphate syn-
thetase I [MIM 311850]) genes encode signaling enzymes
with a role in the degradation of branched-chain fatty
acids and isoleucine, serotonin metabolism, and purine
synthesis, respectively. They are involved in variable forms
of MRXS.
Two G protein–modulator genes, GDI1 (guanosine di-
phosphate dissociation inhibitor 1 [MIM 300104]) and
ARHGEF9 (Rho guanine nucleotide exchange factor 9
[MIM 300429]), appear to be mutated in MRX.
Very recently, Klauck et al. identified mutations in the
RPL10 gene (ribosomal protein L10 [MIM 312173]) in in-
dividuals with autism and MR.85 RPL10 belongs to the
L10e family of ribosomal proteins and is a component of
the 60S large ribosomal subunit, which links the 40S and
80S subunits. Human mutant RPL10 proteins may exhibit
altered translation of synaptic proteins, which may be im-
portant for synthesis of many NRC/MASC and PSD
proteins.
Although the cellular function of many of these X-
linked PSD proteins has been extensively studied, it is
noteworthy that several are not considered to be postsy-
naptic, either because of the lack of specific functional
studies in neurons or because of the expected noncyto-
plasmic subcellular localization (transcription or transla-
tion factors). For instance, several proteins involved in the
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Table 3. X-Linked Genes of the PSP That Are Not Currently Known to Have Mutations in Human
Cognitive Disorders
Gene Locus
KIAA or MGC
Full-Length Clone Cellular Function
PGRMC1 Xq24 MGC8891 Transmembrane receptor
ATP2B3 Xq28 NA Transmembrane receptor
CASK Xp11.4 MGC150920 Scaffolder
CNKSR2 Xp22.12 KIAA0902 Scaffolder
SH3KBP1 Xp22.12 MGC9446 Scaffolder
SEPT6 Xq24 KIAA0128 GTP-binding protein potentially involved in cytokinesis
PSMD10 Xq22.3 MGC9114 Involved in the ATP-dependent degradation of ubiquitinated proteins
DDX3X Xp11.4 MGC20129 Regulation of transcription, splicing and translation
OGT Xq13.1 MGC22921, MGC39117 Protein amino acid O-linked glycosylation
RP2 Xp11.3 KIAA0215 Involved in beta-tubulin folding
IDH3G Xq28 MGC5393, MGC2102 Involved in citric acid cycle in mitochondrion
PDCD8 Xq25 MGC111425 Mitochondrial apoptosis–inducing factor
PDHA1 Xp22.12 MGC8609 Glycolysis, gluconeogenesis, acetyCoA metabolism
HNRPH2 Xq22.1 … Heterogenous nuclear ribonucleoprotein complex (pre-mRNA maturation)
SMARCA1 Xq25 MGC151056 Chromatin remodeling, regulation of transcription
RPS4X Xq13.1 MGC8636, MGC87857 Translation
SYP Xp11.23 MGC70359 Presynaptic vesicle
SLC25A5 Xq24 MGC65136 Ion transporter
MGC4825 Xp22.11 MGC4825 Unknown
IQSEC2 Xp11.22 KIAA0522 Unknown
NOTE.—These genes represent priority targets for future testing and resequencing in X-linked cognitive disorders. Note
that CASK and CNKSR2 also belong to the MASC complex. This list provides the reference of cloned full-length coding cDNA
sequences of most of the genes. NA p not available.
regulation of transcription or translation, such as CDKL5
and RPL10, have been identified in PSD complexes. In-
terestingly, the subcellular localization of the CDKL5 pro-
tein is primarily nuclear, as shown in several reports,86,87
but a weak cytoplasmic signal suggests that this protein
can also exhibit some protein-protein interactions in this
compartment. Indeed, the presence of four SH3-binding
sites at its C-terminal part could lead to the formation of
specific interactions with numerous PSD proteins that pos-
sess such SH3 domains. Dystrophin is not generally con-
sidered to be present at the PSD (e.g., in Duchenne mus-
cular dystrophy), but several studies showed that this
protein is localized subcellularly to the PSD.88–90 Further-
more, Kim et al. demonstrated that dystrophin was absent
from the PSD proteins in the brain of a patient with Duch-
enne muscular dystrophy but was present in the brain of
an age-matched control.91 It is also important to note that
the PSD and NRC/MASC isolation and mass spectrometry
methods are not perfect and that lists of proteins will con-
tain a low level of contaminants, as well as exclude some
proteins that failed to be detected. Thus, refinement in
methods and sample preparation will lead to updated lists
of PSP proteins.
XLMR Genes outside the PSP
Clearly, not all XLMR genes encode for proteins in post-
synaptic complexes; of the 70 XLMR genes identified to
date, 19 (27%) fall into the PSP categories. It is interesting
to consider how, if at all, the non-PSP XLMR genes are
functionally connected to the PSP XLMR genes. Clearly,
NRC/MASC proteins could be regulated by enzymes and
pathways outside the synapse (e.g., trafficking and post-
translational modifications), and we can consider that the
effects of mutation in non-PSP XLMR mediate their effects
by alteration of NRC/MASC and PSD. Toward this, it is
known that a significant proportion of non-PSP XLMR
genes code for proteins involved in signal transduction
and regulation of transcription and those that impact syn-
aptic function and dendrite development.
At least five proteins are directly involved in synaptic
function and activity: FMRP, which binds to and is in-
volved in the metabolism of neuronal mRNAs, including
PSD-95, whose localization and regulated translation play
central roles in neurite outgrowth and synaptic plasticity
(S. G. N. Grant, unpublished data)92; OPHN1 (oligo-
phrenin 1 [MIM 300127]); PAK3 (p21-activated kinase 3
[MIM 300142]); FGD1 (FYVE, RhoGEF, and PH domain–
containing protein 1 [MIM 300546]); and ARHGEF6 (Rho
guanine nucleotide exchange factor 6 [MIM 300267]),
which are required for the regulation of the RhoGTPase
signaling pathway. These proteins integrate extracellular
and intracellular signals to orchestrate coordinated
changes in the actin cytoskeleton, which is essential for
directed neurite outgrowth and the regulation of synaptic
connectivity.93
Very recently, Tarpey et al. identified mutations in the
gene encoding the sigma 2 subunit of the adaptor protein
1 complex (AP1S2 [MIM 603532]) causing XLMR.94 AP1S2
encodes an adaptin protein that constitutes part of the
adaptor protein complex found at the cytoplasmic face of
coated vesicles located at the Golgi complex. The complex
mediates the recruitment of clathrin to the vesicle
membrane. Tarpey et al.94 propose that aberrant endocytic
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Figure 4. Human and mouse mutations and the cognitive disorders affecting specific NRC/MASC signaling pathways and other post-
synaptic proteins. The NMDA receptor subunits (NR1 and NR2) are linked to MAGUK proteins (SAP102 and PSD-95) that bind SynGAP,
which regulates the Ras-ERK-RSK pathway. This pathway regulates transcription (e.g., CREB), cell adhesion (via L1CAM), and AMPA
receptors. MAGUKs, including DLG3/SAP102, coordinate the postsynaptic signaling response to NMDA receptor (NR1 and NR2) activation.
The MAP kinase pathway is an important limb of this response, leading to changes in transcription factors such as RSK2, which, in
turn, send feedback to modify AMPA receptor function and thus produce synaptic plasticity. Note that FMRP, encoded by the FMR1
gene, does not belong to this complex but is involved in the regulation of PSD-95 translation via mGluR activation.52 Note that the
NRC/MASC–associated signaling pathway is involved in MRX as well as MRXS. The molecules are shaded in yellow if there is a known
mouse mutation that results in cognitive dysfunction, and red letters indicate if mutation is in a human gene.
processing through disruption of adaptor protein com-
plexes is likely to result from the AP1S2 mutations iden-
tified in the families with XLMR and that such defects
may cause abnormal synaptic development and function.
Interestingly, we previously identified11 several PSD pro-
teins that participate in the formation of the clathrin ves-
icle (see table A1 [online only]).
Many of the non-PSP genes code for proteins involved
in chromatin remodeling and regulation of transcription,
which would mean that controlled activation/repression
of their targeted genes may be crucial for cognitive func-
tion. A good example is the MECP2 gene (methyl-CpG–
binding protein 2 [MIM 300005]), which causes Rett syn-
drome and XLMR and acts as a transcriptional silencer of
neuronal genes. Particularly, MECP2 regulates the expres-
sion of the gene encoding brain-derived neurotrophic fac-
tor (BDNF [MIM 113505]), a secreted protein that has cru-
cial roles in survival, development, and synaptic plasticity
in the nervous system.95 Thus, it is not surprising that
defects affecting these signaling cascades going from the
postsynaptic membrane to the nucleus, which are pivotal
for the formation of learning and the memory, lead to
cognitive impairments.
Autosomal PSP Genes and MR-Associated Diseases
The high percentage of X-linked genes in NRC/MASC
(85%) and PSD (49%) is indicative of similar roles of au-
tosomal genes in MR. Of the 1,180 genes coding PSP pro-
teins, 11,000 are located on the autosomes and can be
considered potential candidates in psychiatric disorders;
thus, the expectation is that the majority of MR genes will
be found on autosomes and will include many NRC/MASC
genes. Indeed, we curated literature on autosomal NRC/
MASC genes in disease, and almost 50 genes were involved
in various brain disorders.30
Several autosomal genes have already been implicated
in autosomal MRX and MRXS.40,47 Interestingly, recent
studies have pointed out the involvement of some PSD
ion channels in MR associated with autistic disorder.
Splawski et al. found gain-of-function mutations in the
CACNA1C (calcium channel, voltage-dependent, L type,
alpha-1C subunit [MIM 114205]) gene in individuals af-
fected by multiorgan dysfunction, cognitive abnormali-
ties, and autism.96 The encoded protein is involved in cal-
cium-induced calcium release and the calcium intra-
cellular signaling pathway. Recently, the haploinsuffi-
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ciency of the KCNMA1 (potassium channel, calcium-ac-
tivated, large conductance, subfamily M, alpha member 1
[MIM 600150]) gene has been involved in autism and
MR.97 The knockout mouse model for this gene showed
some behavioral alterations and cerebellar Purkinje neu-
rons dysfunction.98
Thanks to the development of genomewide screening
technologies such as BAC–comparative genomic hybrid-
ization arrays, the association of de novo chromosomal
disorders associated with autosomal MR (microdeletions,
duplications, or translocations) has led to the definition
of genomic territories encompassing genes of PSD pro-
teins. For instance, Willatt et al. described a form of MRXS
associated with a 1.5-Mb 3q29 microdeletion.99 The de-
letion encompasses 22 genes, including PAK2 (p21-acti-
vated kinase 2 [MIM 605022]) and DLG1 (discs large,
Drosophila, homolog of, 1 [MIM 601014]), which are au-
tosomal homologues of two known XLMR genes, PAK3
and DLG3. The encoded DLG1 protein (also named
“SAP97”) belongs to the NRC/MASC complex and is also
linked to AMPA receptors (table A1 [online only] and fig.
4). Very recently, Shaw-Smith et al. reported that a recur-
rent 500- to 650-kb microdeletion located at 17q21.3 is
associated with developmental delay and learning dis-
ability.100 Interestingly, this deletion encompasses the
MAPT (microtubule-associated protein tau [MIM 157140])
gene, which encodes a protein present in the PSD
complex.
Conclusions
Network Organization and Integration of Postsynaptic
Signaling
The function of NRC/MASC in synaptic physiology and
behavior has been studied using both reductionist single-
gene strategies and, more recently, large-scale systems-bi-
ology approaches.27,28 As discussed above, the phenotypes
of single gene mutations (in humans and mice) have sup-
ported the biochemical model that the NRC/MASC com-
plex is important as an overall structure in cognition. At
the cell biological level, where it has been extensively stud-
ied using mutations and drugs in brain slices, the NRC/
MASC complex is necessary for the process of induction
of synaptic plasticity. This induction involves the detec-
tion of patterns of synaptic activity and the initiation of
biochemical pathways that lead to changes in the property
of the synapse and other parts of the neuron. The fact
that NRC/MASC proteins are involved with activation of
local synaptic events, such as changes in AMPA receptors
and dendritic spine structure, as well as distant events at
the nucleus, indicates that the complex must coregulate
these processes.
The coregulation of multiple cell biological processes
(e.g., receptor trafficking and protein translation and tran-
scription) by NRC/MASC can be accounted for by the net-
work properties of the protein interactions within the
complexes (figs. 2 and 3).28 In this model, activation of
kinases and phosphatases and other enzymes is followed
by a high degree of cross talk and interaction between
proteins and pathways. In this way, signals are integrated
and many proteins play a role in the final outcome, which
includes the driving and orchestration of the downstream
biological processes. This model has been supported by
statistical and experimental data. Another important fea-
ture of the networks is that they can account for the prop-
erty of robustness to perturbation; that is, the loss of any
single gene only partially interferes with the overall pro-
cess that the complex is involved with, such as induction
of synaptic plasticity. The severity of the phenotype of the
single-gene mutation is a reflection of the degree of con-
nectivity of the protein with other parts of the complex.
More details of the robustness are described in the work
by Pocklington et al., in which the connectivity of pro-
teins was plotted as a function of the mutational
phenotype.27,28
These network models provide a logical process to ex-
tend the human genetics of cognition beyond finding in-
dividual genes and toward understanding gene interac-
tions. When the view that more than one gene is involved
in function of the complex (and cognition) is considered,
then the relative position (connectivity) of those two
genes will influence the phenotype. This principle is valid
for NRC/MASC genes, since epistasis was observed among
three genes when tested using double knockouts.101 One
future approach is to examine the frequency of alleles of
NRC/MASC genes and their combinations in groups of
individuals with cognitive deficits and disorders. An ad-
ditional exciting dimension to these network models of
genetic disorders is the prospect that therapeutic inter-
ventions can be predicted for molecular targets that could
rescue the mutation. For example, if a mutation affects a
component of a signaling pathway within the complex,
then a drug may be able to activate some compensatory
pathway that is connected via a set of local protein in-
teractions. These approaches may open new therapeutic
opportunities for some of these currently untreated con-
ditions of XLMR.
The model of a postsynaptic signaling network is sim-
plified here, and it should be noted that the effects of
mutations on this network will result not only in altered
signaling at diseased synapses but also in changes in neu-
ronal structure. The NMDA receptor is a well-known reg-
ulator of synaptic morphology, as are many postsynaptic
proteins.1,5,6 Furthermore, dendritic spines that contain
the NRC/MASC are irregularly shaped and have abnormal
densities in a number of cognitive disorders characterized
by MR, such as MRX, Down syndrome, Angelman syn-
drome, and autism.102–105 It is also important to consider
that some PSD gene deficits lead to MR with or without
brain abnormalities. This would mean that not only can
the PSD complex be important for the establishment and
maintenance of synaptic connection and activity but that
it can also be crucial for the structure of some brain
regions; for instance, L1CAM mutations are associated
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with agenesis of the corpus callosum and hydrocephalus
(table 2), and ATRX and SYN1 mutations cause micro-
cephaly. The relative contribution to morphological
changes and their differences in brain regions may also
reflect the developmental and regional expression profiles
of these genes.
The molecular networks described for the NRC/MASC
can now be extended to the other proteins in the PSD and
to non-PSP genes, to provide more-comprehensive mo-
lecular neuronal networks. The landscape of these net-
works and the locations of disease genes may ultimately
provide logic to the behavioral phenotypes of patients.
Cognition and the X Chromosome
Beyond disease genetics, the molecular understanding of
synaptic processes and the X chromosome may shed light
on wider issues in behavioral science. Genes on the X
chromosome not only influence general intelligence but
also have relatively specific effects on social cognition and
emotional regulation. Zechner et al. suggest that the X
chromosome has been engaged in the development of
sexually selected characteristics for at least 300 million
years and that natural selection has favored the devel-
opment of X-linked genes that are associated with higher
cognitive abilities.106 Moreover, Skuse proposes that male
and female brains may differ not only because of their
contrasting genetic constitutions but also because of their
sex-steroid environments and that differences in cognitive
and social abilities between the sexes could be directly
linked to the influence of X-chromosome genes.33 Another
study pointed out that the contribution of X-linked genes
to cognition is significantly higher than would be ex-
pected.47 Interestingly, a recent study reported that X-
linked genes are highly expressed in brain tissues of several
mammalian species, and it showed a greater proportion
of highly expressed X-linked genes in human versus
mouse brain.107 These data suggest that, through evolu-
tion, the X chromosome has become a repository for genes
highly expressed in brain and that such genes may have
a role in enhancing cognitive functions.
Summary
Here, we have integrated studies of human X-linked dis-
eases with mouse genetic and proteomic studies of the
PSP. It is clear that proteomic profiling of NRC/MASC and
PSD proteins provides a rich source of disease-relevant
genes. The data from human and mouse genetic studies
also support the model that the NRC/MASC is necessary
for cognitive function. In the near term, we suggest two
important future directions: (i) comprehensive and sys-
tematic studies of NRC/MASC and PSP genes in human
brain disorders with the use of genetic methods and (ii)
systems biology–based approaches to the synapse with the
use of large-scale data sets integrated with bioinformatics
approaches. These approaches, which are being pursued
in the G2C project, should provide a novel foundation
for future therapeutic developments aimed at treating
common cognitive disorders. Detailed lists of the proteins
described here are available in table A1 (online only), to-
gether with curated data on human genetic disorders and
mouse mutations in the G2C database. This neurobio-
logical approach of integration of proteomics, mouse and
human genetics, and network biology is generally appli-
cable to any biological or pathological condition.
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